Switch theme
Sign up to access all valuation multiples
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
2009
710
LTM Revenue $773M
LTM EBITDA -$119M
$2.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Apellis Pharmaceuticals has a last 12-month revenue (LTM) of $773M and a last 12-month EBITDA of -$119M.
In the most recent fiscal year, Apellis Pharmaceuticals achieved revenue of $781M and an EBITDA of -$155M.
Apellis Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Apellis Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $773M | XXX | $781M | XXX | XXX | XXX |
| Gross Profit | $649M | XXX | $664M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | -$119M | XXX | -$155M | XXX | XXX | XXX |
| EBITDA Margin | -15% | XXX | -20% | XXX | XXX | XXX |
| EBIT | -$157M | XXX | -$165M | XXX | XXX | XXX |
| EBIT Margin | -20% | XXX | -21% | XXX | XXX | XXX |
| Net Profit | -$224M | XXX | -$198M | XXX | XXX | XXX |
| Net Margin | -29% | XXX | -25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $41.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Apellis Pharmaceuticals's stock price is $20.
Apellis Pharmaceuticals has current market cap of $2.5B, and EV of $2.6B.
See Apellis Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.6B | $2.5B | XXX | XXX | XXX | XXX | $-1.78 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Apellis Pharmaceuticals has market cap of $2.5B and EV of $2.6B.
Apellis Pharmaceuticals's trades at 3.3x EV/Revenue multiple, and -16.8x EV/EBITDA.
Equity research analysts estimate Apellis Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Apellis Pharmaceuticals has a P/E ratio of -11.1x.
See valuation multiples for Apellis Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | -21.7x | XXX | -16.8x | XXX | XXX | XXX |
| EV/EBIT | -16.5x | XXX | -15.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.1x | XXX | -12.5x | XXX | XXX | XXX |
| EV/FCF | -37.4x | XXX | -29.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialApellis Pharmaceuticals's last 12 month revenue growth is 10%
Apellis Pharmaceuticals's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $1.2M for the same period.
Apellis Pharmaceuticals's rule of 40 is -115% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Apellis Pharmaceuticals's rule of X is 10% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Apellis Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | -15% | XXX | -20% | XXX | XXX | XXX |
| EBITDA Growth | -68% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -115% | XXX | -10% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 10% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 106% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apellis Pharmaceuticals acquired XXX companies to date.
Last acquisition by Apellis Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Apellis Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Apellis Pharmaceuticals founded? | Apellis Pharmaceuticals was founded in 2009. |
| Where is Apellis Pharmaceuticals headquartered? | Apellis Pharmaceuticals is headquartered in United States of America. |
| How many employees does Apellis Pharmaceuticals have? | As of today, Apellis Pharmaceuticals has 710 employees. |
| Who is the CEO of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's CEO is Dr. Cedric Francois, M.D.. |
| Is Apellis Pharmaceuticals publicy listed? | Yes, Apellis Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Apellis Pharmaceuticals? | Apellis Pharmaceuticals trades under APLS ticker. |
| When did Apellis Pharmaceuticals go public? | Apellis Pharmaceuticals went public in 2017. |
| Who are competitors of Apellis Pharmaceuticals? | Similar companies to Apellis Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's current market cap is $2.5B |
| What is the current revenue of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's last 12 months revenue is $773M. |
| What is the current revenue growth of Apellis Pharmaceuticals? | Apellis Pharmaceuticals revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Apellis Pharmaceuticals? | Current revenue multiple of Apellis Pharmaceuticals is 3.4x. |
| Is Apellis Pharmaceuticals profitable? | Yes, Apellis Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's last 12 months EBITDA is -$119M. |
| What is Apellis Pharmaceuticals's EBITDA margin? | Apellis Pharmaceuticals's last 12 months EBITDA margin is -15%. |
| What is the current EV/EBITDA multiple of Apellis Pharmaceuticals? | Current EBITDA multiple of Apellis Pharmaceuticals is -21.7x. |
| What is the current FCF of Apellis Pharmaceuticals? | Apellis Pharmaceuticals's last 12 months FCF is -$69.4M. |
| What is Apellis Pharmaceuticals's FCF margin? | Apellis Pharmaceuticals's last 12 months FCF margin is -9%. |
| What is the current EV/FCF multiple of Apellis Pharmaceuticals? | Current FCF multiple of Apellis Pharmaceuticals is -37.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
